Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering nets $304.7mm for Guardant Health

Executive Summary

Precision oncology firm Guardant Health Inc. netted $304.7mm through the public offering of 4.5mm common shares at $71. The company markets two liquid biopsy products--Guardant360 and GuardantOMNI--which are used in treatment selection and drug development settings, respectively, and is also developing assays for cancer recurrence detection and early disease screening.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies